UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023248
Receipt number R000026708
Scientific Title Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIs
Date of disclosure of the study information 2016/07/20
Last modified on 2022/07/26 16:45:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIs

Acronym

JP-CLEAR
(Japanese Prospective evaluation of tumor-derived Circulating DNA Liquid biopsy in patients with EGFR-mutant NSCLC during and after Acquired Resistance to EGFR-TKI treatment)

Scientific Title

Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIs

Scientific Title:Acronym

JP-CLEAR
(Japanese Prospective evaluation of tumor-derived Circulating DNA Liquid biopsy in patients with EGFR-mutant NSCLC during and after Acquired Resistance to EGFR-TKI treatment)

Region

Japan


Condition

Condition

Non-small cell Lung Cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the diagnostic value of plasma ctDNA of EGFR mutations in the trajectory of patients with EGFR activating mutation-positive non-small cell lung cancer(NSCLC)treated with EGFR-TKIs , including a third-generation TKI

Basic objectives2

Others

Basic objectives -Others

Diagnostic value

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

*The plasma DNA T790M positivity rates by Cobas EGFR Mutation Test in the T790M positive tumors patients.
*The plasma DNA T790M positivity rates at each clinical point.

Key secondary outcomes

*The plasma DNA EGFR Exon 19 deletion or Exon 21 L858 mutation positivety rates in clinical courses
*Time from plasma T790 positivity to tissue T790M positivity in the tissue T790M-positive cases
*Response Rate and PFS with Osimertinib
*Response Rate and PFS with rechallenge of other EGFR-TKIs


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)Patients diagnosed as having advanced or postoperative recurrent NSCLC prior to enrollment
2)Patients diagnosed as carrying activating EGFR mutation by each institution (exon19 deletion, exon 21 L858R mutation, or other minor mutations such as exon 18 G719X)
3)Those being treated without progression, or to be treated with, an EGFR-TKI as anticancer therapy
4)ECOG PS 0-2
5)20 years old over
6)Submitted signed informed consent

Key exclusion criteria

1)Prior treatment with EGFR-TKI
2)HBsAg or HCV-RNA positive Patients
3)HIV positive Patients

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideo Kunitoh

Organization

Japanese Red Cross Medical Center

Division name

Department of Medical Oncology

Zip code


Address

4-1-22 Hiroo, Shibuya-ku, Tokyo

TEL

03-3400-1311

Email

kunito-hideo@med.jrc.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akira Yamao

Organization

Public Health Reseach Foundation

Division name

Comprehensive Support Project for Oncology Research

Zip code


Address

1-1-7 Nishi-waseda,Shinjuku-ku,Tokyo

TEL

03-5287-2636

Homepage URL


Email

cspor-lc05@csp.or.jp


Sponsor or person

Institute

PHRF

Institute

Department

Personal name



Funding Source

Organization

Astra Zeneca K K

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

No

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岩手県立中央病院(岩手県)、群馬県立がんセンター(群馬県)、国立病院機構 渋川医療センター(群馬県)、春日部市立医療センター(埼玉県)、さいたま赤十字病院(埼玉県)、杏林大学医学部付属病院(東京都)、国立研究開発法人 国立国際医療研究センター病院(東京都)、昭和大学病院(東京都)、虎の門病院(東京都)、日本赤十字社医療センター(東京都)、NTT東日本関東病院(東京都)、社会福祉法人 三井記念病院(東京都)、昭和大学藤が丘病院(神奈川県)、藤沢市民病院(神奈川県)、関西電力病院(大阪府)


Other administrative information

Date of disclosure of the study information

2016 Year 07 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

122

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 07 Month 27 Day

Date of IRB

2016 Year 08 Month 05 Day

Anticipated trial start date

2016 Year 08 Month 10 Day

Last follow-up date

2020 Year 03 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

All patients who has given consent to participate in the study during from 2016/08/01 to 2017/3/31


Management information

Registered date

2016 Year 07 Month 20 Day

Last modified on

2022 Year 07 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026708


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name